KR890005074A - 항알레르기제 및 소염제로서의 2-아릴 치환된 헤테로사이클릭 화합물 - Google Patents

항알레르기제 및 소염제로서의 2-아릴 치환된 헤테로사이클릭 화합물 Download PDF

Info

Publication number
KR890005074A
KR890005074A KR1019880012576A KR880012576A KR890005074A KR 890005074 A KR890005074 A KR 890005074A KR 1019880012576 A KR1019880012576 A KR 1019880012576A KR 880012576 A KR880012576 A KR 880012576A KR 890005074 A KR890005074 A KR 890005074A
Authority
KR
South Korea
Prior art keywords
phenyl
compound
methoxy
thiazolyl
methanesulfonamide
Prior art date
Application number
KR1019880012576A
Other languages
English (en)
Inventor
헨리 무서 존
한스 빌헬름 벤더 라인홀드
프랭크 크레프트 3세 안토니
Original Assignee
로저 더블류.캡
아메리칸 홈 프러덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로저 더블류.캡, 아메리칸 홈 프러덕츠 코포레이션 filed Critical 로저 더블류.캡
Publication of KR890005074A publication Critical patent/KR890005074A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

내용 없음

Description

항알레르기제 및 소염제로서의 2-아릴 치환된 헤테로사이클릭 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 일반식(I)의 화합물 및 약제학적으로 허용되는 이의 염.
    상기식에서, X는또는 -N=이고 ; Y는
    는
    (여기에서, n은 각각 독립적으로 0 내지 5이다)이며; R2는 각각 독립적으로, 수소, 저급알킬, 저급알콕시, 저급알콕시카보닐, 트리플루오로메틸, 니트로, 시아노 또는 할로이고 ;
    W는 하나의 결합 또는 -O-, -S- 또는이며; m은 1 내지 15이고 ; R4는 각각 독립적으로 수소 또는 저급알킬이며 ; R5는 저급알킬, 모노플루오로저급알킬, 디플루오로저급알킬, 폴리플루오로저급아킬, 퍼플루오로저급알킬 또는이고; R6은 수소, 저급알킬, -COOR4또는(R4)2이며 ; R7은 수소 또는 메틸이다.
  2. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[[2-(4-메톡시페닐)-5-메틸-4-옥사졸릴]메톡시]페닐]메탄설폰아미드인 화합물.
  3. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(5-메틸-2-페닐-4-옥사졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  4. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-페닐-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  5. 제1항에 있어서, 1,1,1-트리플루오로-N-[2-[(2-메틸-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  6. 제1항에 있어서, 5-[[3-(2-페닐-4-티아졸릴-메톡시)페닐]메틸]-1H-테트라졸인 화합물.
  7. 제1항에 있어서, N,N-디에틸-N′-[2-하이드록시-2-[3-(2-페닐-4-티아졸릴메톡시)페닐]에틸]-N-메틸우레아인 화합물.
  8. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-페닐-6-피리디닐)메톡시)페닐]메탄설폰아미드인 화합물.
  9. 제1항에 있어서, N-[(4-메틸페닐)설포닐]-3-[(2-페닐-4-티아졸릴)메톡시]벤즈아미드인 화합물.
  10. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(4-클로로페닐)-4-티아졸릴]메톡시)페닐]메탄설폰아미드인 화합물.
  11. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(4-플루오로페닐)-4-티아졸릴]메톡시)페닐]메탄설폰아미드인 화합물.
  12. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(2-플루오로페닐)-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  13. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(2,6-디플루오로페닐)-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  14. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(4-트리플루오로메틸페닐)-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  15. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(3-트리플루오로메틸페닐)-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  16. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(2-트리플루오로메틸페닐)-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  17. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(4-메톡시페닐)-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  18. 제1항에 있어서, 1,1,1-트리플루오로-N-[3-[(2-(벤질)-4-티아졸릴)메톡시)페닐]메탄설폰아미드인 화합물.
  19. 제1항에 있어서, 3-[(2-(2-플루오로페닐)-4-티아졸릴)메톡시)벤조산 하이드라지드인 화합물.
  20. 제1항에 있어서, 5-[3-[(2-(2-플루오로페닐)-4-티아졸릴)메톡시)페닐]-1,3,4-옥사디아졸-2(3H)-온인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880012576A 1987-09-30 1988-09-29 항알레르기제 및 소염제로서의 2-아릴 치환된 헤테로사이클릭 화합물 KR890005074A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/103,224 US4826990A (en) 1987-09-30 1987-09-30 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US103,224 1987-09-30

Publications (1)

Publication Number Publication Date
KR890005074A true KR890005074A (ko) 1989-05-11

Family

ID=22294038

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880012576A KR890005074A (ko) 1987-09-30 1988-09-29 항알레르기제 및 소염제로서의 2-아릴 치환된 헤테로사이클릭 화합물

Country Status (5)

Country Link
US (1) US4826990A (ko)
EP (1) EP0310370A1 (ko)
JP (1) JPH01143856A (ko)
KR (1) KR890005074A (ko)
GB (1) GB2210368B (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2592042B1 (fr) * 1985-12-19 1988-03-25 Ile De France Nouveaux ortho-anisamides, leur procede d'obtention, et leurs applications therapeutiques
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4886814A (en) * 1986-03-13 1989-12-12 Dr. Karl Thomas Gmbh Substituted thiazoles and oxazoles and 2-hydroxy-morpholines
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
CA2004911A1 (en) * 1988-12-22 1990-06-22 Mitsuaki Ohta 4,5,6,7-tetrahydrobenzimidazole derivatives
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU645112B2 (en) * 1990-08-23 1994-01-06 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
US5294722A (en) * 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5639770A (en) * 1992-05-29 1997-06-17 Otsuka Pharmaceutical Co., Ltd. Thiazole derivatives
AU657413C (en) * 1992-05-29 2007-05-03 Otsuka Pharmaceutical Co., Ltd. Thiazole derivatives for the release of superoxide radical
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
US5952360A (en) * 1997-08-28 1999-09-14 Eli Lilly And Company Method for treating neuropathic pain
JP2001513532A (ja) * 1997-08-28 2001-09-04 イーライ・リリー・アンド・カンパニー 痛みを処置するための方法
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU9575698A (en) * 1997-10-06 1999-04-27 Eli Lilly And Company Novel compounds useful as neuro-protective agents
AU742641B2 (en) * 1998-01-28 2002-01-10 Shionogi & Co., Ltd. Novel tricyclic compound
AU2002213467A8 (en) * 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
WO2002094264A1 (en) * 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
TW200302728A (en) 2002-02-01 2003-08-16 Novartis Ag Substituted amines as IgE inhibitors
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
JP2007522247A (ja) * 2004-02-11 2007-08-09 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 細胞増殖の阻害を示すアナログ、それを作製する方法およびその使用
BRPI0509468A (pt) * 2004-04-01 2007-09-11 Aventis Pharma Inc 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
NZ549823A (en) * 2004-04-01 2009-12-24 Aventis Pharma Inc 1,3,4-oxadiazol-2-ones as PPAR delta modulators
AU2005243384A1 (en) * 2004-05-17 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Thiazole compound and use thereof
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
BRPI0513858B8 (pt) * 2004-07-27 2021-05-25 Hoffmann La Roche compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
WO2006110626A1 (en) * 2005-04-12 2006-10-19 Merck & Co., Inc. Amidopropoxyphenyl orexin receptor antagonists
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2099757B1 (en) * 2006-11-16 2014-06-25 Allergan, Inc. Sulfoximines as kinase inhibitors
WO2008119662A1 (en) * 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
EP2398500B1 (en) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
CA2760945A1 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
DK2917212T3 (da) * 2012-11-08 2019-09-23 Univ Rutgers Antimikrobielle midler
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
CA3015768A1 (en) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
WO2018183917A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594425A (en) * 1984-02-09 1986-06-10 American Home Products Corporation Heterocyclic compounds as antiallergic agents
US4581457A (en) * 1984-09-21 1986-04-08 American Home Products Corporation Heterocyclic sulfonamides
IE58870B1 (en) * 1985-03-08 1993-11-17 Leo Pharm Prod Ltd Pyridine derivatives
US4754043A (en) * 1985-10-03 1988-06-28 American Home Products Corporation Oxazole and thiazole naphthalenes as antiallergic agents
JPS62142168A (ja) * 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤

Also Published As

Publication number Publication date
GB2210368B (en) 1992-03-25
AU2289688A (en) 1989-04-06
AU611714B2 (en) 1991-06-20
US4826990A (en) 1989-05-02
JPH01143856A (ja) 1989-06-06
GB2210368A (en) 1989-06-07
EP0310370A1 (en) 1989-04-05
GB8822839D0 (en) 1988-11-02

Similar Documents

Publication Publication Date Title
KR890005074A (ko) 항알레르기제 및 소염제로서의 2-아릴 치환된 헤테로사이클릭 화합물
RU2201924C2 (ru) Морфолиновое производное и фармацевтическая композиция на его основе
RU2379299C2 (ru) Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов
KR920019784A (ko) 벤조이소티아졸 및 벤조이소옥사졸-3-카복스아미드, 이의 제조방법 및 약제로서의 용도
DE3852565T2 (de) Aryl-heteroaryl-karbinol-Derivate mit analgetischer Aktivität.
FI963238A0 (fi) Heteroaromaattisia oksatsoli yhdisteitä ja niiden käyttö
NO933093D0 (no) Monohydrat av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2h-indol-2-on hydroklorid
CA2059363A1 (en) Benzo¬5,6|cyclohepta¬1,2-b|pyridine derivatives and antiallergic agents comprising same
NO934740L (no) Forbindinger vedrörende benzotiofener
ES512275A0 (es) "procedimiento para preparar espiro (piperidino-oxobenzoxazinas) substituidas en posicion 1 anti-hipertensivas".
DE3874576T2 (de) 4-(4-(4-(4-((2-(2,4-difluorophenyl)-2-(1h-azolylmethyl)-1,3-dioxolan-4-yl)-methoxy)phenyl)-1-piperazinyl)phenyl)triazolone.
JP2005519885A5 (ko)
HUT56809A (en) Herbicidal composition comprising 2-(2', 3', 4'-trisubstituted benzoyl)-1,3-cyclohexanedione derivatives as active ingredient
SE8802412D0 (sv) Thiourea derivatives
TR200400237T4 (tr) Yeni karışımlar.
KR910000684A (ko) 소염제 페나메이트 1,3,4-티아디아졸 및 1,3,4-옥사디아졸
SE7906461L (sv) N-substituerade aziridin-2-karbonsyraderivat
DE69129076T2 (de) 2-(2'-methyl-3',4'-trisubstituierte benzoyl)-1,3-cyclohexandione
SE8303117L (sv) Alfa-(1-triazolyl)-keto-derivat med fungicid aktivitet
KR870004006A (ko) 5-아릴-2,4-디알킬-3h-1,2,4-트리아졸-3-티온 및 이의 제조 방법
RU2002111343A (ru) Производные бензамидина
NO870251D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazopyridiner.
SE8506125L (sv) 8alfa-acylaminoergoliner, deras framstellning och farmaceutiska kopositioner innehallande dessa
DK0926144T3 (da) Syntese af 2-(methylsulfonyl)-5-(triflourmethyl)-1,3,4-thiadizol i nærværelse af iseddikesyre som katalysator
JPS5285138A (en) Salicylanilides

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid